Peterson Richard G, Jackson Charles Van, Zimmerman Karen M
Crown Bioscience Indiana7918 Zionsville Rd, Indianapolis 46268, Indiana, USA.
Am J Transl Res. 2017 Sep 15;9(9):4236-4249. eCollection 2017.
The ZDSD rat is a new obese-diabetic rat model that expresses type 2 diabetes in the presence of an intact leptin pathway. During a long pre-diabetic state, the animals exhibit most of the features of metabolic syndrome including obesity, hyperlipidemia, hypertension, insulin resistance and decreased glucose disposal. The animals used in these studies were either allowed to become spontaneously diabetic at 16-30 weeks of age, or diabetes was induced with a diabetogenic diet. In the presence of either spontaneous or diet-induced diabetes, they develop progressive albuminuria as well as increases in other urinary markers of impaired renal function (kidney injury molecule-1 (KIM-1), β2-microglobulin, clusterin and cystatin C). Typical morphological changes of nephropathy, such as glomerular capillary basement membrane thickening and podocyte effacement, accompany these marker increases. Lisinopril (ACEi) treatment (30 mg/kg/day via the diet) dramatically reduced diabetes-induced albuminuria by 85%, independent of the duration of diabetes or the initial albumin excretion. These results position the ZDSD rat as a relevant model of diabetic nephropathy that can be treated with clinically effective compounds.
ZDSD大鼠是一种新的肥胖糖尿病大鼠模型,在瘦素通路完整的情况下表现出2型糖尿病。在漫长的糖尿病前期状态下,这些动物表现出代谢综合征的大多数特征,包括肥胖、高脂血症、高血压、胰岛素抵抗和葡萄糖清除率降低。这些研究中使用的动物要么在16至30周龄时自然发生糖尿病,要么通过致糖尿病饮食诱导糖尿病。在自然发生或饮食诱导的糖尿病情况下,它们会出现进行性蛋白尿以及其他肾功能受损的尿液标志物(肾损伤分子-1(KIM-1)、β2-微球蛋白、簇集素和胱抑素C)增加。肾病的典型形态学变化,如肾小球毛细血管基底膜增厚和足细胞消失,伴随着这些标志物的增加。赖诺普利(ACEi)治疗(通过饮食给予30mg/kg/天)显著降低了糖尿病诱导的蛋白尿85%,与糖尿病持续时间或初始尿白蛋白排泄无关。这些结果表明ZDSD大鼠是一种可被临床有效化合物治疗的糖尿病肾病相关模型。